Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer.
Setti M, Bignardi D, Ballestrero A, Ferrando F, Musselli C, Blanchi S, Basso M, Bosco O, Balleari E, Patrone F, Indiveri F. Setti M, et al. Among authors: musselli c. Cancer Immunol Immunother. 1999 Sep;48(6):287-96. doi: 10.1007/s002620050577. Cancer Immunol Immunother. 1999. PMID: 10473803 Free PMC article. Clinical Trial.
[The immunological activity of corticosteroids].
Scudeletti M, Musselli C, Lanza L, Peirano L, Puppo F, Indiveri F. Scudeletti M, et al. Among authors: musselli c. Recenti Prog Med. 1996 Oct;87(10):508-15. Recenti Prog Med. 1996. PMID: 9026858 Review. Italian.
T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.
Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ, Livingston PO, Williams L, Lewis JJ, Houghton AN, Chapman PB. Schaed SG, et al. Clin Cancer Res. 2002 May;8(5):967-72. Clin Cancer Res. 2002. PMID: 12006508 Clinical Trial.
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).
Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A; Elispot Proficiency Panel of the CVC Immune Assay Working Group. Janetzki S, et al. Cancer Immunol Immunother. 2008 Mar;57(3):303-15. doi: 10.1007/s00262-007-0380-6. Epub 2007 Aug 25. Cancer Immunol Immunother. 2008. PMID: 17721781 Free PMC article.
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI. Slovin SF, et al. Among authors: musselli c. Cancer Immunol Immunother. 2005 Jul;54(7):694-702. doi: 10.1007/s00262-004-0598-5. Epub 2005 Feb 22. Cancer Immunol Immunother. 2005. PMID: 15726361 Free PMC article. Clinical Trial.
25 results